Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis and BeiGene ended their partnership on a cancer immunotherapy for a target called TIGIT. Though BeiGene describes the termination as mutual, it comes before Novartis would need to pump more money into the alliance even as questions linger about TIGIT as a cancer target.
A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.
A new vaccine boosts the response of engineered CAR-T cells and helps the immune system generate T cells that target other tumor antigens. The researchers found this approach made it more likely that a tumor can be eradicated in mice.
Immunotherapy is among the newest and most potent weapons against cancer. It prompts the immune system to recognize tumors as intruders in the body and attack. But not all patients respond well to immunotherapy. Why? Scientists aren't always sure.
Ultrasound is a promising technique for treating cancer. Unlike laser light, used in photodynamic cancer therapy, ultrasound waves can reach deep into tissue-;up to 12 cm-;to treat deep tumors without damaging healthy cells.